HealthDay - No Definitive Link Seen Between Vytorin and Cancer
New research finds no definitive link between Vytorin and cancer risk, but it also suggests that the cholesterol-lowering drug cannot curb cardiovascular disease.
The results of a small study published recently suggested that Vytorin (ezetimibe) might boost the chances of developing cancer. In that study, called SEAS, researchers found that among patients taking Vytorin, 101 developed cancer, compared with 65 in the control group. Among these patients, 39 taking Vytorin died, compared with 23 in the control group.
Most Popular
5 Regular Mistakes In Public Speaking
10 Jobs That Pay $30 An Hour
3 Questions No Job Seeker Ever Wants To Be Asked?
13 Job Interview Mistakes To Avoid
Public Speaking: 7 Secrets Of Great Public Speakers
However, a three-study analysis in the Sept. 2 issue of the New England Journal of Medicine did not find compelling evidence of such a connection. A second study in the same issue of the journal found that taking Vytorin with a statin did not benefit patients with abnormal narrowing of the aortic valve called aortic stenosis.
“Overall, the three ezetimibe trials show no credible evidence of any effect on cancer …
Read the full article with a Free Trial at MyWire.
